Trends in Pharmacy Compounding for Women's Health in North Carolina: Focus on Vulvodynia.

Southern Medical Journal (Impact Factor: 0.93). 07/2014; 107(7):433-436. DOI: 10.14423/SMJ.0000000000000138
Source: PubMed

ABSTRACT Objectives:
To identify trends in compounding pharmacies with a focus on women's health and, more specifically, the types and combinations of medications used in the treatment of vulvodynia.

This survey study was conducted with 653 nonchain pharmacies that compound medications. Each pharmacy was asked to complete a 19-item online survey assessing general practice and common compounding indications, focusing on women's health.

Of the 653 pharmacies contacted, 200 (31%) responded to our survey. Women's health issues ranked third (19%) among the common indications for compounding, preceded by otolaryngology (30%) and dermatology (28%). Of the medications compounded for women's health, the most common indication was bioidentical hormone therapy (73%) followed closely by vaginal dryness (70%) and low libido (65%). Vulvodynia, or vulvar pain, was the fourth most common indication for compounding medication for women's health issues (29%). Vulvovaginal infections were reported as an indication for compounding medications by 16% of respondents.

Vulvovaginal symptoms are a common indication for compounding medications in women's health. Further research in understanding the rationale for using compounded medications, even when standard treatments are available for some of these symptoms (eg, vaginal dryness, vulvovaginal infections), is warranted.

Download full-text


Available from: Denniz Zolnoun, Apr 20, 2015
34 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Most reported associations in observational clinical research are false, and the minority of associations that are true are often exaggerated. This credibility problem has many causes, including the failure of authors, reviewers, and editors to recognize the inherent limitations of these studies. This issue is especially problematic for weak associations, variably defined as relative risks (RRs) or odds ratios (ORs) less than 4. Such associations, commonly reported in the medical literature, are more likely to be attributable to bias than to causal association. All observational research has bias (which can include selection, information, and confounding bias). Hence, detection of small associations falls below the discriminatory ability of observational studies. In general, unless RRs in cohort studies exceed 2 to 3 or ORs in case-control studies exceed 3 or 4, associations in observational research findings should not be considered credible. However, these guidelines are not foolproof: strong (yet spurious) associations can result when large amounts of bias are present. Only in a properly performed randomized controlled trial, free of bias, should small associations merit attention. Better training and more circumspection on the part of investigators, tougher editorial standards on the part of journals, and hefty skepticism on the part of referees and readers are necessary to avoid the dangers of false alarms, pseudo-epidemics, and their unfortunate consequences.
    Obstetrics and Gynecology 10/2012; 120(4):920-7. DOI:10.1097/AOG.0b013e31826af61a · 5.18 Impact Factor
  • Source
    American Journal of Health-System Pharmacy 10/2004; 61(18):1928-38. · 1.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pharmaceutical compounding—the process by which a pharmacist combines ingredients into a customized medication for an individual patient—has ancient roots, with popularity that has waxed and waned throughout history. Elderly individuals and other long-term care patients may be among those who need customized medications, so pharmacists should be aware of the current scope and regulations for compounded medications.
    The Consultant pharmacist: the journal of the American Society of Consultant Pharmacists 06/2010; 25(6):357-63. DOI:10.4140/TCP.n.2010.357